Savara Initiates Early Access Program for Rare Lung Disease Treatment

MT Newswires Live
2024-09-27

Savara (SVRA) said Friday it has launched an Early Access Program for molgramostim, allowing physicians of eligible patients with autoimmune pulmonary alveolar proteinosis to request the investigational inhalation solution in select regions where it is not yet commercially available.

The program has been reviewed and allowed to proceed by the US Food and Drug Administration, and is expected to expand through 2026, Savara said, adding it aims to complete a Biologics License Application submission for molgramostim as a treatment for aPAP to the FDA in H1 2025.

Shares of the company were up nearly 1% in recent Friday premarket activity.

Price: 4.2800, Change: +0.04, Percent Change: +0.94

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10